Advanced chronic myelomonocytic leukemia in elderly and frail patients managed by azacitidine in the field of clinical practice

Advanced chronic myelomonocytic leukemia in elderly and frail patients managed by azacitidine in... Ann Hematol (2017) 96:1591–1593 DOI 10.1007/s00277-017-3064-0 LETTER TO THE EDITOR Advanced chronic myelomonocytic leukemia in elderly and frail patients managed by azacitidine in the field of clinical practice 1 1 1 1 Pasquale Niscola & Andrea Tendas & Elisabetta Abruzzese & Tommaso Caravita & 1 1 1 1 Luca Cupelli & Marco Giovannini & Laura Scaramucci & Agostina Siniscalchi & 1 1 Monika Malgorzata Trawinska & Paolo de Fabritiis Received: 3 June 2017 /Accepted: 4 July 2017 /Published online: 12 July 2017 Springer-Verlag GmbH Germany 2017 Dear Editor, for the role of azacitidine in the CMML management, Chronic myelomonocytic leukemia (CMML) is an despite an overall response rate (ORR) and median aging-related clonal hematopoietic stem cell disorder, overall survival (OS) ranging from 39 to 60% and from classified as myelodysplastic/myeloproliferative disor- 12 to 37 months respectively reported by some studies ders [1]. Indeed, its disease phenotype usually combines [4–7] outside clinical trials, a matched-pair analyses of myelodysplastic (MD) and myeloproliferative (MP) fea- real-life CMML patients showed that this epigenetic tures. Therefore, other than a persistent peripheral agent do not modify the natural course of the disease monocytosis representing the hematological disease hall- [5]. Therefore, with the exception of patients http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Hematology Springer Journals

Advanced chronic myelomonocytic leukemia in elderly and frail patients managed by azacitidine in the field of clinical practice

Loading next page...
 
/lp/springer_journal/advanced-chronic-myelomonocytic-leukemia-in-elderly-and-frail-patients-0iMyL2MUR7
Publisher
Springer Berlin Heidelberg
Copyright
Copyright © 2017 by Springer-Verlag GmbH Germany
Subject
Medicine & Public Health; Hematology; Oncology
ISSN
0939-5555
eISSN
1432-0584
D.O.I.
10.1007/s00277-017-3064-0
Publisher site
See Article on Publisher Site

Abstract

Ann Hematol (2017) 96:1591–1593 DOI 10.1007/s00277-017-3064-0 LETTER TO THE EDITOR Advanced chronic myelomonocytic leukemia in elderly and frail patients managed by azacitidine in the field of clinical practice 1 1 1 1 Pasquale Niscola & Andrea Tendas & Elisabetta Abruzzese & Tommaso Caravita & 1 1 1 1 Luca Cupelli & Marco Giovannini & Laura Scaramucci & Agostina Siniscalchi & 1 1 Monika Malgorzata Trawinska & Paolo de Fabritiis Received: 3 June 2017 /Accepted: 4 July 2017 /Published online: 12 July 2017 Springer-Verlag GmbH Germany 2017 Dear Editor, for the role of azacitidine in the CMML management, Chronic myelomonocytic leukemia (CMML) is an despite an overall response rate (ORR) and median aging-related clonal hematopoietic stem cell disorder, overall survival (OS) ranging from 39 to 60% and from classified as myelodysplastic/myeloproliferative disor- 12 to 37 months respectively reported by some studies ders [1]. Indeed, its disease phenotype usually combines [4–7] outside clinical trials, a matched-pair analyses of myelodysplastic (MD) and myeloproliferative (MP) fea- real-life CMML patients showed that this epigenetic tures. Therefore, other than a persistent peripheral agent do not modify the natural course of the disease monocytosis representing the hematological disease hall- [5]. Therefore, with the exception of patients

Journal

Annals of HematologySpringer Journals

Published: Jul 12, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off